



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : A61K 38/15, 9/08, 9/19</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/42125 (43) International Publication Date: 26 August 1999 (26.08.99)</p>
<p>(21) International Application Number: PCT/GB99/00511 (22) International Filing Date: 18 February 1999 (18.02.99) (30) Priority Data: 9803448.1 18 February 1998 (18.02.98) GB (71) Applicant (for AT AU BE BR CA CH CY DE DK ES FI FR GB GR IE IT JP KR LU MC MX NL NZ PT RU SE UA only): PHARMA MAR, S.A. (ES/ES); Poligono Industrial de Tres Cantos, Calle de la Calera, 3, E-28760 Tres Cantos (ES). (71) Applicant (for all designated States except AT AU BE BR CA CH CY DE DK ES FI FR GB GR IE IT JP KR LU MC MX NL NZ PT RU SE UA US): RUFFLES, Graham, Keith (GB/GB); 57-60 Lincoln's Inn Fields, London WC2A 3LS (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BEIJNEN, Jacob, Hendrik (NL/NL); (NL); NUYEN, Bastiaan (NL/NL); (NL); HENRAR, Roland, Elizabeth, Cornelis (NL/NL); New Drug Development Office (NDDO), Free University Hospital, Gebouw Zuid, Amstelveenseweg 601, NL-1081 JC Amsterdam (NL); GOMEZ, Andres (ES/ES); Pharma Mar, S.A., Poligono Industrial de Tres Cantos, Calle de la Calera, 3,</p>	<p>E-28760 Tres Cantos (ES). JIMENO, Jose (ES/ES); Pharma Mar, S.A., Poligono Industrial de Tres Cantos, Calle de la Calera, 3, E-28760 Tres Cantos (ES). (74) Agent: RUFFLES, Graham, Keith; Marks & Clerk, 57-60 Lincoln's Inn Fields, London WC2A 3LS (GB). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: PHARMACEUTICAL FORMULATION OF A DIDEMNIN COMPOUND</p>		
<p>(57) Abstract</p> <p>A stable pharmaceutical composition of a didemnin compound, comprises firstly a lyophilised didemnin preparation including water-soluble material and secondly a reconstitution solution of mixed solvents.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MY	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroun	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PHARMACEUTICAL FORMULATION OF A DIDEMNIN COMPOUND

The present invention relates to a pharmaceutical formulation, and more particularly a pharmaceutical formulation of a didemnin compound.

THE BACKGROUND

US Patent 5,294,603 to Rinehart claims a pharmaceutical composition comprising a didemnin, in combination with a pharmaceutically acceptable carrier, excipient or diluent. In that patent, extensive results are given for testing for biological activity, notably assay results for cytotoxicity and antiviral activity.

THE PROBLEM

In practice, there are some difficulties in preparing pharmaceutical compositions of didemnin compounds suited for administration to patients, and there is especially a need for a stable parental pharmaceutical dosage form. More specifically, didemnin compounds such as dehydroidemnin B, also known as aplidine, require mixing with bulking agents, such as mannitol, for optimal,

stable preparation of pharmaceutical dosage forms, in particular lyophilised preparations,

Certain bulking agents for this purpose, such as mannitol, require water for solubilisation, while drugs such as apidine are poorly soluble in water. However, drug delivery to patients requires resuspending of the lyophilised materials before use.

THE INVENTION

The present invention solves the problem by providing a pharmaceutical composition of a didemnin compound, comprising firstly a lyophilised didemnin preparation including water-soluble materials and secondly a reconstitution solution of mixed solvents. The mixed solvents comprise an aqueous solvent, with the water serving to dissolve the water soluble material and the other solvent serving to dissolve the didemnin compound.

PREFERRED EMBODIMENTS

The pharmaceutical formulation of this invention is typically a stable parental pharmaceutical dosage form suited for reconstitution for administration to patients as an antitumor treatment. The invention solves the problem for drugs such as apidine, which must be presented as lyophilised mixtures of two or more substances soluble in incompatible solvents. It preferably

provides, separately bottled or otherwise contained, a premixed three component surfactant/alkanol/water mixture of solvents. In order to allow for proper resuspension of such pharmaceutical dosage forms, the separately packaged solvent mixture is provided to be added to the dry lyophilised preparations containing the drug and water soluble substances such as mannitol, before administration for treatment of disease.

Preferred didemnins compounds for the pharmaceutical compositions of this invention include didemnins and didemnin derivatives, such as dehydroididemnins, nordidemnins, didemnin congeners and didemnin analogs. The present invention is particularly directed at didemnins with limited water solubility, including for example dehydroididemnin B, also known as aplidine.

The antitumour agent aplidine (dehydroididemnin B) is a natural occurring cyclic depsipeptide isolated from the Mediterranean runicate *Aplidium albicans*. Aplidine has been characterised by using several chromatographic and spectrometric techniques. Solubility testing showed that aplidine exhibits poor aqueous solubility. Moreover, the long-term stability of aplidine in solution is currently unknown.

The lyophilised didemnin preparation is preferably prepared by freeze drying a didemnin/alkanol/water mix, especially using t-butanol as the alkanol. The alkanol/water mix suitably contains 25 to 60% v/v alkanol. A bulking agent such as mannitol can

also be included, though other conventional water-soluble additives may be included, known to be of utility in the preparation of such lyophilised dosage forms.

The reconstitution solution preferably comprises a surfactant/alkanol/water mix, especially using a nonionic surfactant and ethanol as the alkanol. The surfactant is suitably 10 to 25% v/v of the mix; the alkanol is suitably 10 to 25% v/v of the mix; and the water is suitably 50 to 80% v/v of the mix.

EXAMPLES

Freeze-drying was performed from a 1.0 mg/ml solution aplidine in 40% v/v t-butanol in water for injection ("WFI") containing 25 mg/ml mannitol as bulking agent. Differential scanning calorimetry studies were conducted to determine the freeze-drying cycle parameters. The prototype, containing 1.0 mg aplidine and 25 mg mannitol per vial was found to be the optimal formulation in terms of solubility, length of the freeze-during cycle and dosage requirements.

A solution composed of 15/15/70% (v/v/v) Cremophor EL/ethanol absolute/WFI was found to be the optimal reconstitution solution, Cremophor EL being a glycerol-polyethylene glycol ricinoleate available from BASF in Germany.

Dilutions of reconstituted product with normal saline up to 1:200 showed it to be stable for at least 24 hours after preparation. Quality control of the freeze-dried formulation demonstrated that the manufacturing process does not change the integrity of aplidine. Shelf-life data, available thus far, show that the formulation is stable for at least 6 months when stored at +4°C in the dark.

Thus, the preferred aplidine product of this invention is a dual-package containing:

an injection vial containing aplidine 1 mg/vial lyophilized product, and an injection vial containing 2 ml of 15/15/70% (v/v/v) Cremophor EL/ethanol/water as reconstruction solution.

The use of 15/15/70% (v/v/v) Cremophor EL/ethanol/water as reconstitution solution for a lyophilized product is unprecedented. Thus far, the combination of Cremophor EL/ethanol in commercial available products has been used exclusively as solution vehicle (e.g., taxol or cyclosporine).

The development of the Cremophor EL/ethanol/water vehicle provides a potent co-solvent/surfactant system which can be applied as reconstitution solution in future drug formulations and allows the addition of a water soluble bulking agent such as mannitol. Furthermore, by decreasing the relative amount of Cremophor EL, a less toxic vehicle is created.

The manufacturing procedure of the lyophilized product has also a special feature. Normally, freeze-drying of a drug is performed from a drug solution in water. In the case of aplidine, a 40% (v/v) t-butanol/water mixture is preferably used as freeze-drying medium. Although previously described (e.g. rhizoxin), freeze-drying from a 40% t-butanol/water mixture is not common practice.

In conclusion, the combination of lyophilisation of a drug from a t-butanol/water mixture and the subsequent reconstitution of the lyophilized product with 15/15/70% (v/v/v) Cremophor EL/ethanol/water is unique.

CLAIMS:

1. A pharmaceutical composition of a didemnin compound, comprising firstly a lyophilised didemnin preparation including water-soluble material and secondly a reconstitution solution of mixed solvents.
2. A didemnin composition according to claim 1, intended for reconstitution for administration to patients as an antitumor treatment.
3. A didemnin composition according to claim 1 or 2, wherein the didemnin is chosen from didemnins, dehydroidemnins, nordidemnins, didemnin congeners and didemnin analogs.
4. A didemnin composition according to claim 3, wherein the didemnin compound is aplidine.
5. A didemnin composition according to any preceding claim, wherein the reconstitution solution comprises an alkanol/water mix.
6. A didemnin composition according to claim 5, wherein the reconstitution solution includes a nonionic surfactant.
7. A didemnin composition according to claim 6, wherein the nonionic surfactant is 10 to 25% v/v of the solution; the

alkanol is ethanol and is 10 to 25% v/v of the solution; and the water is 50 to 80% v/v of the solution.

8. A didemninn composition according to any preceding claim, which comprises a vial of lyophilised didemninn preparation including a water-soluble bulking agent, and a separate vial of a premix of non-ionic surfactant/ethanol/water.
9. A method of preparing a pharmaceutical composition of a didemninn compound, which comprises freeze drying a didemninn/water-soluble additive/alkanol/water mix to provide a lyophilised first component, and separately providing an alkanol/water mix as reconstitution solution.
10. A method according to claim 9 wherein the alkanol in the mix is t-butanol.
11. A method according to claim 9 or 10 wherein the amount of alkanol in the alkanol/water mix is 25 to 60% v/v.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/GB 99/00511

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/15 A61K9/08 A61K9/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 048 149 A (UNIVERSITY OF ILLINOIS FOUNDATION) 24 March 1982 (1982-03-24) page 8, line 1 - line 4; example 6 page 18, line 29 - page 19, line 6 & US 5 294 603 A cited in the application	1-11
A	US 4 670 262 A (G. BATTELLI ET AL.) 2 June 1987 (1987-06-02) column 2, line 20 - line 29; claims 1,8,9; example III	1-11
A	US 5 462 726 A (N.J. LODGE) 31 October 1995 (1995-10-31) column 5, line 62 - line 66; claims 1-5; example 4	1-11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "S" document member of the same patent family

Date of the actual completion of the international search

26 July 1999

Date of mailing of the international search report

30/07/1999

Name and mailing address of the ISA
European Patent Office, P.B. 5018 Patentkan 2
NL - 2220 HV Rijswijk
Tel: (+31-70) 340-3040, Tx: 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Ryckebosch, A

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/00511

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 48149 A	24-03-1982	JP 1684261 C	31-07-1992
		JP 3049919 B	31-07-1991
		JP 57081413 A	21-05-1982
		US 4950649 A	21-08-1990
		US 4782135 A	01-11-1988
		US 5137870 A	11-08-1992
		US 4493796 A	15-01-1985
		US 5294603 A	15-03-1994
		US 4548814 A	22-10-1985
US 4670262 A	02-06-1987	AT 382077 B	12-01-1987
		AU 559499 B	12-03-1987
		AU 1908983 A	29-03-1984
		BE 897761 A	02-01-1984
		CA 1211372 A	16-09-1986
		CH 655852 A	30-05-1986
		DE 3333024 A	29-03-1984
		DK 424383 A, B,	24-03-1984
		FI 833300 A, B,	24-03-1984
		FR 2533439 A	30-03-1984
		GB 2127291 A, B	11-04-1984
		GR 79055 A	02-10-1984
		IE 56173 B	08-05-1991
		JP 59078117 A	04-05-1984
		NL 8303211 A	16-04-1984
		SE 464061 B	04-03-1991
		SE 8304920 A	24-03-1984
		SU 1424722 A	15-09-1988
		ZA 8306904 A	31-10-1984
US 5462726 A	31-10-1995	NONE	